Search PubMed⌕ Search

Biomedical subjects

M J Tong

Publications and source records attributed to M J Tong.

At least 73 records · Page 4Linked to original sources
PubMed1986

Histologic and clinicopathologic features of Chinese patients with HBsAg-positive chronic active hepatitis.

Needle biopsies of both the right and left lobes of the liver were performed during peritoneoscopy in 20 male patients with chronic active hepatitis B in Taiwan. Microscopic study of these biopsy specimens led to the recognition of three groups: 1) five patients in whom the lobular architecture was easily recognizable but in whom necrosis and early intralobular fibrosis were present, along with severe chronic inflammation of the portal tracts; 2) seven patients in whom the livers were characterized by early septal formation and a good regenerative response, but few recognizable lobules with normal architecture; and 3) eight patients in whom the disease had progressed to severe fibrosis with septal formation and tiny pseudolobules, indicative of early cirrhosis. The left lobe was the more severely damaged in 16 of the 20 patients.

Adolescent↗
PubMed1985

Clinical, serologic, and immunologic effects of human leukocyte interferon in HBsAg-positive primary hepatocellular carcinoma.

Five patients with hepatitis B surface antigen (HBsAg) positive chronic hepatitis and histologically confirmed primary hepatocellular carcinoma (PHC) were treated with 3 X 10(6) units/day of partially purified human leukocyte interferon intramuscularly for 2 consecutive months. During interferon therapy, one patient had stable disease, while the remaining four patients had progressive disease. Following interferon therapy no changes were noted in the hepatitis B viral markers or in serum alphafetoprotein levels. Data on the effects of human leukocyte interferon on lymphocyte subpopulations and on the cytotoxic activity of peripheral blood mononuclear cells against a hepatitis B surface antigen expressing primary hepatocellular carcinoma cell line are presented.

Adult↗
PubMed1985

Prevention of hepatitis B infection by hepatitis B immune globulin in infants born to mothers with acute hepatitis during pregnancy.

Eleven infants born to mothers with acute hepatitis B during the third trimester of pregnancy who were hepatitis B surface antigen-positive at delivery were treated with hepatitis B immune globulin within 24-48 h of birth. Five infants received one dose of hepatitis B immune globulin and 6 infants received a second dose at 1 mo of age. During the average 12.5-mo follow-up period, only 1 of 11 (9%) treated infants became hepatitis B surface antigen-positive and this individual developed acute hepatitis B at 9.5 mo of age and recovered. Twenty-four infants born to mothers with acute hepatitis B during the third trimester of pregnancy who were untreated served as historical controls. Of these, 17 (71%) showed evidence for hepatitis B infection and 15 (62.5%) became chronic hepatitis B virus carriers. This study shows that administration of hepatitis B immune globulin to infants born to mothers with acute hepatitis B is effective in preventing perinatal transmission of the hepatitis B virus. With the availability of the hepatitis B virus vaccine, the current recommendation is to give hepatitis B immune globulin to such infants within 24 h of birth, followed by three doses of the hepatitis B virus vaccine beginning soon after birth, and again 1 and 6 mo later.

Adult↗
PubMed1985

Alterations in the immune response of nonresponders to the hepatitis B vaccine.

The phenotypic characteristics of peripheral blood lymphocytes (PBLs) from responders and nonresponders to hepatitis B (HB) vaccine and their response to pokeweed mitogen (PWM) stimulation in vitro were compared. The nonresponders had significantly higher absolute numbers and percentages of T11+, HNK-1+, and T8+ lymphocytes. Also, after PWM stimulation, PBLs from HB-vaccine nonresponders had impaired IgG and IgM production and failed to produce antibodies to HB surface antigen in vitro. These findings suggest that healthy individuals who fail to produce such antibodies have a higher population of suppressor lymphocytes that alters their normal immune response to HB vaccination.

Adult↗
PubMed1985

Liver involvement in sickle cell disease.

In an effort to clarify the features of hepatic dysfunction in sickle cell disease, we obtained serial tests of liver function in 100 consecutive patients with sickle cell anemia and in 30 consecutive patients with hemoglobinopathy SC during a five-year period. There were 32 patients with chronic abnormalities in tests of liver function. These abnormal tests were explained by a variety of lesions in 30 cases, and the liver disease remained unexplained in only 2 patients who declined liver biopsy. The diagnoses in these 30 patients included hepatitis, chronic passive congestion, common duct obstruction, alcoholic liver disease, pregnancy, collagen-vascular disease, and sarcoidosis. Evidence for hepatitis B infection was present in 19 of those with sickle cell anemia and in 6 of those with hemoglobinopathy SC. The bilirubin levels in sickle cell anemia appeared to have a trimodal distribution, with six patients exhibiting markedly elevated levels of indirect bilirubin suggesting a difference in bilirubin metabolism. There was no evidence of liver disease in 72 patients with sickle cell anemia, nor in 24 patients with hemoglobinopathy SC, as these patients exhibited only mild elevation of their serum indirect bilirubin levels owing to chronic hemolysis. Intrasinusoidal sickling and Kupffer cell erythrophagocytosis were nearly universal findings at liver biopsy, irrespective of the clinical disorder, and were not related to the degree of liver test abnormalities. Liver and biliary tract dysfunction in sickle cell disease have been attributed to anoxia secondary to sinusoidal obstruction by sickled erythrocytes and Kupffer cell erythrophagocytosis. However, some causes of liver disease in sickle cell patients can be explained by clinical disorders other than the hemoglobinopathy alone.(ABSTRACT TRUNCATED AT 250 WORDS)

Acute Disease↗
PubMed1985

Effects of short-term, high-dose prednisone treatment of patients with HBsAg-positive chronic active hepatitis.

We conducted a clinical trial to study the effects of a 10-week course of prednisone therapy and its withdrawal on serum aminotransferase levels and on hepatitis B virus (HBV) markers in patients with hepatitis B surface antigen (HBsAg) positive chronic active hepatitis (CAH-B). Eighteen patients with CAH-B were treated with prednisone, while another 18 patients matched for age, sex, race and sexual preference were followed simultaneously without treatment for the same duration. Nine of 18 prednisone-treated patients became transiently DNA polymerase positive. All nine patients developed a transient rise in serum alanine aminotransferase (ALT) levels of greater than 300 U/L above baseline values, which was associated with a drop in HBsAg levels from a mean of 186 micrograms/ml prior to therapy to 92 micrograms/ml at 6 months following treatment. Six of these patients developed fatigue, anorexia and dark urine, and four also developed either ascites or hemorrhage from esophageal varices, which was accompanied by hepatic encephalopathy. All six of these patients had histologic evidence of CAH with cirrhosis. In comparison, none of the control, untreated patients with CAH-B had any change in either HBV markers or serum ALT levels. Therefore, even a short course of prednisone in patients with CAH-B with cirrhosis is detrimental and its use should be discouraged.

Adult↗
PubMed1985

Correlation between peripheral lymphocyte subsets and antibody to hepatitis B surface antigen response in hepatitis B vaccine recipients.

Peripheral lymphocyte subsets of 14 heterosexual recipients of hepatitis B vaccine were measured by indirect immunofluorescence using specific monoclonal antibodies. 12/14 vaccine recipients developed antibody to hepatitis B surface antigen after the second injection of vaccine; however, 2 recipients remained seronegative. Prior to the vaccination, these two vaccine non-responders had been found to have a significantly reduced ratio of peripheral helper-inducer T cells to suppressor/cytotoxic T cells (1.15 +/- 0.02 vs. 1.79 +/- 0.12), and an increase in the proportion of natural killer/killer cells (25.6 +/- 1.5% vs. 13.8 +/- 1.6%) as compared to the 12 responders. Enumeration of peripheral lymphocyte subsets prior to vaccination may be useful in predicting the immune response of hepatitis B vaccine recipients.

Adult↗
PubMed1985

A serological case-control study of primary hepatocellular carcinoma in Guangxi, China.

Guangxi is a very high-risk area for primary hepatocellular carcinoma (PHC); the age-standardized (world population) rates for males and females in that Chinese Autonomous Region were 32.5 and 8.5, respectively. Blood specimens from 50 PHC patients and 50 age- and sex-matched controls in Guangxi were analyzed for hepatitis B surface antigen, antibody to hepatitis B surface antigen, and antibody to hepatitis B core antigen. Eighty-six % of cases were hepatitis B surface antigen positive, compared to 22% of controls (relative risk, 17.0). We estimate from the data that persistent hepatitis B virus infection can account for at least 80% of all PHC cases occurring in Guangxi. The consistency of our findings with those from Hong Kong and Taiwan strongly suggests that hepatitis B virus infection is also an important risk factor for PHC in other parts of southern China.

Adolescent↗
PubMed1984

Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma.

We detected des-gamma-carboxy prothrombin, an abnormal prothrombin, in the serum of 69 of 76 patients (91 per cent) with biopsy-confirmed hepatocellular carcinoma (the mean level of the abnormal prothrombin was 900 ng per milliliter). In contrast, levels of the abnormal prothrombin were low in patients with chronic active hepatitis (mean, 10 ng per milliliter) or metastatic carcinoma involving the liver (mean, 42 ng per milliliter), and undetectable in normal subjects. In five patients treated with vitamin K there was no reduction in abnormal prothrombin, indicating that its presence was not due to vitamin K deficiency. Surgical resection of tumors in two patients and chemotherapy in one patient markedly reduced abnormal-prothrombin concentrations, which later increased with recurrence of disease. Serum alpha-fetoprotein levels correlated poorly with abnormal-prothrombin levels. Together, the assay for abnormal prothrombin and the alpha-fetoprotein assay identified 64 of 76 patients with hepatoma (84 per cent). Abnormal prothrombin may be useful in the laboratory diagnosis of primary hepatocellular carcinoma.

Aged↗
PubMed1984

Prevalence of delta agent among Chinese in Taiwan and Los Angeles.

The prevalence of delta agent among 120 Chinese patients with HBsAg-positive chronic active and hepatocellular carcinoma from Taiwan and Los Angeles were studied by serological assay for antibody to delta antigen and immunoperoxidase staining for delta antigen in the liver biopsies. Of 120 patients, only four with chronic active hepatitis and one with hepatocellular carcinoma from Taiwan had antibody to delta antigen in their sera, while none was detected in the patients from Los Angeles. Indirect immunoperoxidase staining for delta antigen in the liver tissue from three of the patients with circulating anti-delta was positive. Thus, the overall prevalence of delta infection was 5.8% among the 86 patients from Taiwan, and 0% in the 34 Chinese patients from Los Angeles.

Adult↗
PubMed1984

Efficacy of hepatitis B immune globulin in prevention of perinatal transmission of the hepatitis B virus.

An efficacy trial of hepatitis B immune globulin in the prevention of perinatal transmission of hepatitis B virus infection was conducted in Los Angeles. Ten infants born to hepatitis B surface antigen (HBsAg)-and hepatitis B e antigen (HBeAg)-positive carrier mothers as well as 4 infants born to mothers with acute hepatitis B in the third trimester of pregnancy received hepatitis B immune globulin without randomization. Twenty infants born to HBsAg- and antibody to hepatitis B e antigen (anti-HBe)-positive carrier mothers were randomized to receive hepatitis B immune globulin or a placebo. All infants were followed for up to 18 mo. Four infants (2 born to HBeAg carrier mothers, 1 to an anti-HBe carrier, and 1 to a mother with acute hepatitis) became HBsAg-positive carriers, whereas another infant, whose mother was an HBeAg carrier, developed a transient anicteric hepatitis B infection. All infants who became infected did so after 9 mo of age as hepatitis B immune globulin protection waned. In infants born to HBsAg-positive carrier mothers, active immunoprophylaxis with the hepatitis B vaccine must be used in conjunction with hepatitis B immune globulin.

Acute Disease↗
PubMed1983

Alcoholic hepatitis: granulocyte chemotactic factor from Mallory body-stimulated human peripheral blood mononuclear cells.

The characteristic histopathological features of acute alcoholic hepatitis include hyaline degeneration of hepatic parenchymal cells (Mallory bodies), hepatocellular necrosis, and granulocyte infiltration of the liver. The chemotactic response of neutrophils to highly purified Mallory bodies was studied. Mallory bodies, per se, were not chemotactic for granulocytes, nor did they generate chemotactic factors when incubated with serum. However, a factor(s) chemotactic for both granulocytes and mononuclear cells was generated when Mallory bodies were incubated with mononuclear cells, both from patients with alcoholic hepatitis or from normal controls. It was concluded that Mallory bodies stimulate peripheral blood mononuclear cells to release a factor chemotactic for granulocytes and mononuclear cells. This factor may be important in the etiology of the cellular infiltration in the livers of patients with alcoholic hepatitis.

Acute Disease↗